About this item:

75 Views | 53 Downloads

Author Notes:

See publication for full list of authors and conflicts of interest.

Nadine Rouphael, MD, Professor of Medicine, Emory University, Hope Clinic, Emory Vaccine Center, 500 Irvin Court, Suite 200, Decatur, GA, 30030, Tel: 404-712-1435, Fax: 404-499-9727, nroupha@emory.edu

Angela Branche, MD, Associate Professor of Medicine, University of Rochester, 601 Elmwood Avenue, Box 689, Rochester, NY 14642, Tel: 585-273-4104, angela_branche@urmc.rochester.edu

We would like to thank all participants who contributed to the study and the NIAID SARS-CoV-2 Assessment of Viral Evolution (SAVE) program team for their consultation regarding the study arm design and variant vaccine selection.

Subjects:

Research Funding:

This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024 Task Order No. 75N91022F00007 and for EMMES LLC under Division of Microbiology and Infectious Diseases contract # 75N93021C00012. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.

Tools:

Journal Title:

medRxiv

Publisher:

Type of Work:

Article | Preprint: Prior to Peer Review

Abstract:

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Copyright information:

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/).
Export to EndNote